Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib combinations in pediatric relapsed/refractory solid tumors
NCT04238819Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2020
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of abemaciclib in solid tumor and neuroblastoma, sponsored by Eli Lilly and Company. Primary endpoints: Recommended Phase 2 Dose of Abemaciclib in Combination With Irinotecan and Temozolomide at 6 weeks, Number of Participants With Dose Limiting Toxicities in Part A at 3 weeks and 3 more. Started Nov 2020; status: completed.
02
Drugs
abemaciclib
03
Conditions
solid tumorneuroblastoma
Beyond the preview
Go deeper on NCT04238819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238819.